Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for ...
Those that solve artificially simplified problems where quantum advantage is meaningless. Those that provide no genuine quantum advantage when all costs are properly accounted for. This critique is ...
Microsoft Excel includes quick stats via Analysis ToolPak; mean, median, and standard deviation are generated for selected ...
Threat actors are operationalizing AI to scale and sustain malicious activity, accelerating tradecraft and increasing risk for defenders, as illustrated by recent activity from North Korean groups ...
Preterm infants face many challenges in transitioning from the in utero to extrauterine environment while still immature. Failure of the preterm gut to successfully mature to accommodate bacteria and ...
Advantage Energy Ltd. ("Advantage" or the "Corporation") is pleased to report 2025 year-end financial and operating results. Advantage achieved exceptional results during the year, with record ...
Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ...
REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025.
The Tribunal held that the revised ₹25 lakh exemption limit for leave encashment under Section 10(10AA) must be considered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results